GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » Gross Margin %

TELA Bio (TELA Bio) Gross Margin %

: 68.38% (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. TELA Bio's Gross Profit for the three months ended in Dec. 2023 was $11.62 Mil. TELA Bio's Revenue for the three months ended in Dec. 2023 was $17.00 Mil. Therefore, TELA Bio's Gross Margin % for the quarter that ended in Dec. 2023 was 68.38%.


The historical rank and industry rank for TELA Bio's Gross Margin % or its related term are showing as below:

TELA' s Gross Margin % Range Over the Past 10 Years
Min: 35.56   Med: 61.68   Max: 68.62
Current: 68.62


During the past 7 years, the highest Gross Margin % of TELA Bio was 68.62%. The lowest was 35.56%. And the median was 61.68%.

TELA's Gross Margin % is ranked better than
75.75% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.54 vs TELA: 68.62

TELA Bio had a gross margin of 68.38% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for TELA Bio was 10.80% per year.


TELA Bio Gross Margin % Historical Data

The historical data trend for TELA Bio's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only 60.03 61.68 63.85 65.30 68.62

TELA Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.35 66.32 70.38 69.02 68.38

Competitive Comparison

For the Medical Devices subindustry, TELA Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TELA Bio Gross Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Gross Margin % distribution charts can be found below:

* The bar in red indicates where TELA Bio's Gross Margin % falls into.



TELA Bio Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

TELA Bio's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=40.1 / 58.453
=(Revenue - Cost of Goods Sold) / Revenue
=(58.453 - 18.341) / 58.453
=68.62 %

TELA Bio's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=11.6 / 16.998
=(Revenue - Cost of Goods Sold) / Revenue
=(16.998 - 5.374) / 16.998
=68.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


TELA Bio  (NAS:TELA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

TELA Bio had a gross margin of 68.38% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


TELA Bio Gross Margin % Related Terms

Thank you for viewing the detailed overview of TELA Bio's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TELA Bio (TELA Bio) Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
Executives
Gregory A. Firestone officer: Chief Business Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca officer: COO and CFO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Antony Koblish director, officer: Chief Executive Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p. other: See footnotes 1 and 2 280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp 10 percent owner QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p. 10 percent owner CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran director 0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Vincent J Burgess director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Douglas G Evans director 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355